AVENZO THERAPEUTICS
Avenzo Therapeutics specializes in the development of oncology therapies for cancer treatment.
AVENZO THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Medical Oncology Therapeutics
Founded:
2022-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.avenzotx.com
Total Employee:
1+
Status:
Active
Total Funding:
569.35 M USD
Technology used in webpage:
Euro Cloudflare Hosting Pound Sterling
Similar Organizations
Aro Biotherapeutics
Aro Biotherapeutics develops tissue-targeted genetic medicines using Centyrins, a proprietary technology, to address complex diseases.
Avstera Therapeutics
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.
Cello Therapeutics
Specializes in the development of nanoparticles for cancer treatment.
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
NBE-Therapeutics
NBE-Therapeutics is a biotech company that develops oncology treatments for cancer patients.
Fore Biotherapeutics
We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics.
Pinpoint Therapeutics
Pinpoint Therapeutics is a preclinical stage company developing novel cancer treatment options aimed to specifically inhibit autophagy.
Spark Therapeutics
Spark Therapeutics is focused on the development of gene therapy.
Verismo Therapeutics
Verismo Therapeutics develops novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer.
Current Advisors List
Investors List
Deep Track Capital
Deep Track Capital investment in Series A - Avenzo Therapeutics
Quan Capital
Quan Capital investment in Series A - Avenzo Therapeutics
New Enterprise Associates
New Enterprise Associates investment in Series A - Avenzo Therapeutics
Sofinnova Investments
Sofinnova Investments investment in Series A - Avenzo Therapeutics
Sands Capital Ventures
Sands Capital Ventures investment in Series A - Avenzo Therapeutics
INCE Capital
INCE Capital investment in Series A - Avenzo Therapeutics
Delos Capital
Delos Capital investment in Series A - Avenzo Therapeutics
TF Capital
TF Capital investment in Series A - Avenzo Therapeutics
SR One
SR One investment in Venture Round - Avenzo Therapeutics
Lilly Asia Ventures
Lilly Asia Ventures investment in Venture Round - Avenzo Therapeutics
Official Site Inspections
http://www.avenzotx.com Semrush global rank: 5.17 M Semrush visits lastest month: 1.52 K
Unable to get host informations!!!
More informations about "Avenzo Therapeutics"
Avenzo Therapeutics
Keep up with Avenzo on our mission to develop the next generation of oncology therapies for patients.See details»
Avenzo Therapeutics - Crunchbase Company Profile
Avenzo Therapeutics successfully closed a $150 million oversubscribed Series A-1 financing round to advance its emerging oncology pipeline. The company also received a $150 million investment to pursue a licensing strategy and target …See details»
Avenzo Therapeutics - LinkedIn
Exclusive: Avenzo Therapeutics is joining the growing trend of US biotechs in-licensing assets from China-based drug developers as the San Diego startup has inked a deal for VelaVigo's Nectin-4 ...See details»
Avenzo Therapeutics Company Profile 2024: Valuation, …
Avenzo Therapeutics General Information Description. Operator of a clinical-stage oncology platform intended to develop novel treatments for underserved cancers. The company's platform offers a pipeline of oncology drug …See details»
Avenzo Therapeutics Provides Corporate Update and Announces …
Avenzo Therapeutics, Inc., a clinical-stage biotechnology company developing next-generation oncology therapies for patients, today announced it has entered into an exclusive option …See details»
Avenzo Therapeutics Honored by Goldman Sachs for …
SAN DIEGO, October 16, 2024--Athena Countouriotis, M.D., Co-founder, President and CEO Among Most Exceptional Entrepreneurs at 2024 Goldman Sachs Builders and Innovators SummitSee details»
Avenzo Therapeutics - Foresite Capital
Avenzo Therapeutics is developing the next generation of oncology therapies for patients. The company was co-founded and led by Athena Countouriotis, MD, and Mohammad Hirmand, …See details»
Avenzo Therapeutics Honored by Goldman Sachs for …
Oct 16, 2024 Avenzo Therapeutics, Inc., a clinical-stage biotechnology company developing the next generation of oncology therapeutics, today announced that Goldman Sachs is …See details»
Avenzo Therapeutics Announces Global License of AVZO-021 …
Jan 4, 2024 Avenzo Therapeutics, Inc. (Avenzo), a clinical-stage biotechnology company developing next generation oncology therapeutics, today announced that it has entered into an …See details»
Avenzo Therapeutics Announces Appointment of Garry Nicholson …
AVZO-021 is being studied in a Phase 1 study in the U.S. for the treatment of advanced solid tumors. Avenzo is headquartered in San Diego, California. For more information, visit us at …See details»
Avenzo Therapeutics Announces $150 Million Oversubscribed …
SAN DIEGO, March 26, 2024--Avenzo Therapeutics announces the closing of an oversubscribed $150 million Series A-1 financing, bringing total capital raised to $347 million.See details»
Avenzo Therapeutics Announces Global License of AVZO-021 …
Jan 4, 2024 - AVZO-021 demonstrated a potential best-in-class preclinical potency, selectivity and pharmacokinetic profile - AVZO-021 is currently in an ongoing U.S.-based Phase 1 clinical …See details»
Avenzo Therapeutics Honored by Goldman Sachs for …
Oct 16, 2024 For more information, visit us at www.avenzotx.com or on LinkedIn. About Goldman Sachs. Goldman Sachs is a leading global financial institution that delivers a broad …See details»
Avenzo Therapeutics Honored by Goldman Sachs for …
Oct 16, 2024 For more information, visit us at www.avenzotx.com or on LinkedIn. About Goldman Sachs Goldman Sachs is a leading global financial institution that delivers a broad …See details»
Avenzo Therapeutics Announces $150 Million ... - Business Wire
Mar 26, 2024 Carla Taub Media Relations [email protected]. Release Summary. Avenzo Therapeutics announces the closing of an oversubscribed $150 million Series A-1 financing, …See details»
Avenzo Therapeutics Announces Global License of AVZO-021 …
Jan 4, 2024 Avenzo Therapeutics announces global license agreement with Allorion Therapeutics for AVZO-021 (ARTS-021), a potentially best-in-class CDK2 inhibitor.See details»
Avenzo Therapeutics Honored by Goldman Sachs for …
Oct 16, 2024 How we use your personal data How we use your information depends on the product and service that you use and your relationship with us.See details»
Avenzo Therapeutics Announces Appointment of Patrick …
Nov 20, 2024 AVZO-021 is being studied in a Phase 1 study in the U.S. for the treatment of advanced solid tumors, and in combinations in HR+/HER2-negative metastatic breast cancer. …See details»
Terms of Service | Avenzo Therapeutics
Jan 4, 2024 THIS IS A LEGAL AGREEMENT (“AGREEMENT“) BETWEEN YOU, THE END USER (ON BEHALF OF YOURSELF, OR YOUR COMPANY OR ORGANIZATION), AND US. …See details»